(Reuters) - Johnson & Johnson said on Wednesday it expected to file marketing applications for at least 10 new drugs between 2019 to 2023, to strengthen its pharmaceuticals unit which has been a major growth driver.
This is part of the healthcare conglomerate’s plan to deliver above-market growth through 2023 at its Janssen unit, it said. The plan comes ahead of J&J’s business review, scheduled later on Wednesday.
The company said it would discuss four medicines that are new to J&J’s pipeline of drugs at its review as well as therapeutic areas such as gene therapy and RNA therapeutics.
Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur
Our Standards: The Thomson Reuters Trust Principles.